New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 12, 2014
10:00 EDTVECO, SNN, ITRI, EXXI, SCOR, ZTS, TRIP, ROLL, SGNT, SGEN, BUD, WCN, TCBK, PES, CROX, CNVR, SBMRYOn The Fly: Analyst Upgrade Summary
Today's noteworthy upgrades include: Itron (ITRI) upgraded to Buy from Hold at Needham... Pioneer Energy (PES) upgraded to Buy from Speculative Buy at Global Hunter... RBC Bearings (ROLL) upgraded to Buy from Neutral at BofA/Merrill... Smith & Nephew (SNN) upgraded to Buy from Hold at Deutsche Bank... Sprint (S) upgraded to Buy from Hold at Deutsche Bank... TriCo Bancshares (TCBK) upgraded to Strong Buy from Outperform at Raymond James... TripAdvisor (TRIP) upgraded to Outperform from Sector Perform at RBC Capital... Veeco (VECO) upgraded to Outperform from Neutral at Credit Suisse... Waste Connections (WCN) upgraded to Buy from Hold at BB&T... Zoetis (ZTS) upgraded to Outperform from Market Perform at William Blair... SABMiller (SBMRY) upgraded to Conviction Buy from Buy at Goldman... AB InBev (BUD) upgraded to Buy from Sell at Goldman... comScore (SCOR) upgraded at Northland Securities... Conversant (CNVR) upgraded to Buy from Hold at Craig-Hallum... Seattle Genetics (SGEN) upgraded to Buy from Hold at Needham... Energy XXI (EXXI) upgraded to Buy from Accumulate at KLR Group... Crocs (CROX) upgraded to Overweight from Neutral at Piper Jaffray... Sagent Pharmaceuticals (SGNT) upgraded to Outperform at RBC Capital.
News For ITRI;PES;ROLL;SNN;TCBK;TRIP;VECO;WCN;ZTS;SBMRY;BUD;SCOR;CNVR;SGEN;EXXI;CROX;SGNT From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent news | >>
March 26, 2015
07:35 EDTSGNTSagent Pharmaceuticals backs FY15 revenue guidance of $325M-$375M
Subscribe for More Information
07:34 EDTSGNTSagent Pharmaceuticals CEO Jeffrey Yordon retires
The board of Sagent Pharmaceuticals announced that Jeffrey Yordon, chairman and CEO, has informed the board of his decision to retire from the company. He will remain a member of the board. Frank Kung, Ph.D., a member of Sagent's board since 2006, has been named chairman. The board will immediately begin the search for a new CEO. In the interim, the board has formed an Executive Management Committee to lead the company.
06:31 EDTBUDAB InBev close to naming JAB's Goudet chairman, Reuters says
AB InBev (BUD) is close to nominating JAB Holding CEO Olivier Goudet as its next chairman, according to Reuters. A member of the brewer's board since 2011, Goudet is French and his company is one of the most important private investors in global consumer good makers, according to Reuters. JAB also has close ties to 3G Capital, which controls four AB InBev board seats, the news service stated. Reference Link
06:20 EDTBUDKraft Foods shares worth $78 at deal closing, says Citigroup
Subscribe for More Information
March 25, 2015
12:58 EDTZTSPershing Square raises stake in Valeant, says will discuss acquisitions
Subscribe for More Information
10:00 EDTBUDOn The Fly: Analyst Downgrade Summary
Today's noteworthy downgrades include: AB InBev (BUD) downgraded to Reduce from Overweight at HSBC... BreitBurn Energy (BBEP) downgraded to Sell from Neutral at UBS... DiamondRock (DRH) downgraded to Reduce from Neutral at SunTrust... Ethan Allen (ETH) downgraded to Hold from Buy at Gabelli... Felcor Lodging (FCH) downgraded to Neutral from Buy at SunTrust... Finish Line (FINL) downgraded to Neutral from Buy at B. Riley... Hannover Re (HVRRY) downgraded to Sell from Hold at Deutsche Bank... Hersha Hospitality (HT) downgraded to Reduce from Neutral at SunTrust... Host Hotels (HST) downgraded to Reduce from Neutral at SunTrust... ING Groep (ING) downgraded to Neutral from Buy at Goldman... Informatica (INFA) downgraded to Neutral from Buy at Mizuho... Kofax (KFX) downgraded to Hold from Buy at Canaccord... LRR Energy (LRE) downgraded to Sell from Neutral at UBS... LaSalle Hotel (LHO) downgraded to Reduce from Neutral at SunTrust... Munich Re (MURGY) downgraded to Sell from Hold at Deutsche Bank... Orbital ATK (OA) downgraded to Market Perform from Outperform at Wells Fargo... PCTEL, Inc. (PCTI) downgraded to Neutral from Buy at B. Riley... Quest Diagnostics (DGX) downgraded to Hold from Buy at Deutsche Bank... SJW Corp. (SJW) downgraded to Neutral from Outperform at RW Baird... Selective Insurance (SIGI) downgraded to Neutral from Buy at BofA/Merrill... Sonus (SONS) downgraded to Hold from Buy at Wunderlich... Starwood (HOT) downgraded to Neutral from Buy at SunTrust... Synchrony Financial (SYF) downgraded to Neutral from Buy at BofA/Merrill... Tesla (TSLA) downgraded to Underperform from Outperform at CLSA... Twitter (TWTR) downgraded to Hold from Buy at Pivotal Research... ZAGG (ZAGG) downgraded to Market Perform from Outperform at Northland... iDreamSky (DSKY) downgraded to Neutral from Overweight at JPMorgan.
06:28 EDTBUDAB InBev downgraded to Reduce from Overweight at HSBC
HSBC downgraded AB InBev two notches to Reduce from Overweight due to recent share strength. Price target is $111.
March 23, 2015
17:19 EDTPESPioneer Energy sees Q1 service revenue to be down 28%-33%
Subscribe for More Information
10:00 EDTSNNOn The Fly: Analyst Upgrade Summary
Subscribe for More Information
09:52 EDTEXXIEnergy XXI sees Q3 production 58,000-62,000 BOE/d
Subscribe for More Information
09:52 EDTEXXIEnergy XXI lowers 2015 capex view to $640M-$660M
Energy XXI projected FY15 capex of $640M-$660M in slides for its presentation at the Howard Weil energy conference. On February 9, the company had estimated total FY15 capital program to range from $670M-$690M. Energy XXI still sees FY15 production 57,000-61,000 BOE/d. The company said it is pursuing asset monetization for midstream and non-core E&P and that for the combined GoM divestiture with M21K that bids have been received and negotiations are underway with potential buyers. Says annualized savings approaching $170M.
08:22 EDTSGENEditorial on Seattle Genetics AETHERA was positive, says RBC Capital
RBC Capital believes that the Lancet editorial on Seattle Genetics' AETHERA was positive, and the firm expects the drug's label to expand. However, the firm warns that for further upside Seattle Genetics needs one or more programs targeting unmet need with clearly delineated paths to approval. The firm keeps a $50 price target and Outperform rating on the shares.
05:38 EDTSNNSmith & Nephew upgraded to Buy from Neutral at Goldman
Subscribe for More Information
March 20, 2015
14:47 EDTCROXCrocs spikes higher, levels to watch
Subscribe for More Information
14:43 EDTCROXCrocs up 2.3% to $12.20
05:49 EDTEXXIStocks with implied volatility movement; EXXI FXCM
Subscribe for More Information
March 17, 2015
12:44 EDTZTSZoetis management to meet with Piper Jaffray
Subscribe for More Information
10:29 EDTBUDAB InBev downgraded to Underperform from Neutral at Tigress Financial
March 16, 2015
09:37 EDTTRIPActive equity options trading on open
Subscribe for More Information
07:16 EDTSBMRYConsumer Analyst Group of Europe to hold a conference
Subscribe for More Information
1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use